179 related articles for article (PubMed ID: 21458303)
1. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Chen Z; Duldulao MP; Li W; Lee W; Kim J; Garcia-Aguilar J
J Am Coll Surg; 2011 Jun; 212(6):1008-1017.e1. PubMed ID: 21458303
[TBL] [Abstract][Full Text] [Related]
2. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
3. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
4. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
[TBL] [Abstract][Full Text] [Related]
5. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
6. Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer.
Kundel Y; Nasser NJ; Rath-Wolfson L; Purim O; Yanichkin N; Brenner R; Zehavi T; Nardi Y; Fenig E; Sulkes A; Brenner B
Am J Clin Oncol; 2018 Jun; 41(6):613-618. PubMed ID: 27740975
[TBL] [Abstract][Full Text] [Related]
7. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
Tan BR; Thomas F; Myerson RJ; Zehnbauer B; Trinkaus K; Malyapa RS; Mutch MG; Abbey EE; Alyasiry A; Fleshman JW; McLeod HL
J Clin Oncol; 2011 Mar; 29(7):875-83. PubMed ID: 21205745
[TBL] [Abstract][Full Text] [Related]
9. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma.
Luna-Perez P; Arriola EL; Cuadra Y; Alvarado I; Quintero A
Ann Surg Oncol; 1998; 5(3):203-8. PubMed ID: 9607618
[TBL] [Abstract][Full Text] [Related]
10. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
13. Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes.
Calvo FA; Morillo V; Santos M; Serrano J; Gomez-Espí M; Rodriguez M; Del Vale E; Gracia-Sabrido JL; Ferrer C; Sole C
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1651-60. PubMed ID: 24880919
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
15. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
[TBL] [Abstract][Full Text] [Related]
16. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
17. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
[TBL] [Abstract][Full Text] [Related]
18. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]